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A B S T R A C T
The aim of the study was to investigate whether maternal mid-pregnancy 25-hydroxyvitamin D
concentrations are associated with cord blood DNA methylation.
DNA methylation was assessed using the Illumina HumanMethylation450 BeadChip, and maternal
plasma 25-hydroxyvitamin D was measured in 819 mothers/newborn pairs participating in the
Norwegian Mother and Child Cohort (MoBa) and 597 mothers/newborn pairs participating in the Avon
Longitudinal Study of Parents and Children (ALSPAC).
Across 473,731CpG DNA methylation sites in cord blood DNA, none were strongly associated with
maternal 25-hydroxyvitamin D after adjusting for multiple tests (false discovery rate (FDR) > 0.5; 473,731
tests). A meta-analysis of the results from both cohorts, using the Fisher method for combining p-values,
also did not strengthen ﬁndings (FDR > 0.2). Further exploration of a set of CpG sites in the proximity of
four a priori deﬁned candidate genes (CYP24A1, CYP27B1, CYP27A1 and CYP2R1) did not result in any
associations with FDR < 0.05 (56 tests). In this large genome wide assessment of the potential inﬂuence
of maternal vitamin D status on DNA methylation, we did not ﬁnd any convincing associations in 1416
newborns. If true associations do exist, their identiﬁcation might require much larger consortium studies,
expanded genomic coverage, investigation of alternative cell types or measurements of
25-hydroxyvitamin D at different gestational time points.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Vitamin D is a precursor of the steroid hormone 1,25-
dihydroxyvitamin D (1,25(OH)2D), with important roles in calcium
and bone metabolism as well as other biological processes. A
number of different tissues express the vitamin D receptor (VDR),
which acts as a transcriptional factor after binding of 1,25(OH)2D
and heterodimerisation with retinoic X receptor (RXR). The major
circulating form and indicator of vitamin D status, 25-hydrox-
yvitamin D (25(OH)D), is supplied by 25-hydroxylation of vitamin
D produced in the skin upon UVB radiation or vitamin D from the
diet [1]. 25(OH)D is activated in a second hydroxylation step, by* Corresponding author.
E-mail address: matthew.suderman@bristol.ac.uk (M. Suderman).
1 Equally contributing authors.
http://dx.doi.org/10.1016/j.jsbmb.2016.03.005
0960-0760/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access artic1a-hydroxylase (encoded by CYP27B1), primarily in the kidneys,
but also in other tissues expressing CYP27B1 including lympho-
cytes [1,2].
Low 25(OH)D levels have been associated with a range of
adverse conditions, from pregnancy outcomes to childhood
illnesses and chronic disease including osteoporosis, cancer and
cardiovascular disease in adulthood [3], although randomized
controlled trials of vitamin D supplements do not support causality
for extra-skeletal outcomes [4,5].
Vitamin D metabolism changes during pregnancy, suggesting
importance for the mother and fetus [6]. For instance, while
circulating 1,25(OH)2D is normally tightly controlled by renal
hydroxylation of 25(OH)D, levels increase during pregnancy. In
addition to increased renal expression of CYP27B1, this may also
partly result from placental expression of CYP27B1 combined with
reduced activity of CYP24A1, which catalyzes the ﬁrst step of the
catabolism of 1,25(OH)2D.le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Population characteristics.
MoBa ALSPAC
Number of participants used 819 597
Maternal age (years)
Mean  SD 29.9 (4.33) 30.1 (4.38)
Maternal mid-pregnancy 25-hydroxy vitamin D (ng/mL)
Mean  SD 73.5 (23.42) 68.3 (32.3)
Maternal folate levels (nmol/L)
Mean +/ SD 12.0 (7.99) N/A
Maternal pre-pregnancy BMI (kg/m2)
Median  SD 23.2 (4.15) 22.9 (3.71)
Maternal education
Low 61 52 (CSE)
High school 258 52 (Vocational)
College 367 198 (O level)
University 129 172 (A level)
114 (Degree)
Maternal smoking during pregnancy
Yes 110 88
No 702 463
Maternal parity
First child 346 275
Second child 333 215
Third or more 140 89
Offspring sex
Male 449 288
Female 370 309
Offspring asthma at 3 yrs
Yes 328 81 (wheezing)
No 491 516
Birth season
Feb–Apr 267 121
May–Jul 172 161
Aug–Oct 136 181
Nov–Jan 244 134
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with a number of adverse perinatal outcomes, such as low birth
weight and preterm birth and also later health outcomes in the
offspring such as bone health [7], wheezing and atopic disorders
[8], and autoimmune disorders like type 1 diabetes [9]. Although a
number of studies have reported inverse associations between
maternal vitamin D status and postnatal health outcomes,
systematic reviews show that there is still substantial heteroge-
neity between studies in terms of methodology and results, and
few or no randomized trials have been performed [6,8,10,11].
Although two recent randomized controlled trials observed
suggestive reductions in the incidence of asthma and recurrent
wheezing following vitamin D supplementation during pregnancy
[12,13], the primary endpoints were not statistically signiﬁcant.
The evidence for causality of these associations therefore remains
largely inconclusive.
In addition to a need for large randomized studies in this ﬁeld,
there is also a need to explore potential mechanisms involved in
the hypothesized links between maternal vitamin D status and
offspring health. It is well established that maternal 25(OH)D
during pregnancy is correlated with cord blood 25(OH)D, but it is
possible that some of the observed associations with long term
health outcomes may be mediated by fetal programming mecha-
nisms such as DNA methylation in the fetal genome [14]. The
activated vitamin D receptor has a large number of potential target
genes, identiﬁed both experimentally using in vitro models and insilico by identiﬁcation of vitamin D responsive elements [15].
Potential target genes included some well-established candidates,
such as CYP27B1 and CYP24A1, and a large number of yet
unconﬁrmed genes.
A few smaller studies have investigated DNA methylation at
some candidate loci in relation to vitamin D [16]. One recent study
examined the association between vitamin D deﬁciency and
genome wide DNA methylation in African children [17]. Another
study explored epigenetic regulation of vitamin D converting
enzymes [18], while a third found a relationship between
methylation of the genes CYP24R1 and CYP27A1 and variations
in circulating 25(OH)D levels [19]. Epigenome wide studies, in
general, are gaining in popularity with the use of the Illumina
HumanMethylation450 BeadChip. We are not aware of any
published studies on the association between maternal 25(OH)D
and genome wide DNA methylation in cord blood. We assessed this
association using the Illumina HumanMethylation450 assay in
1416 newborns from two large pregnancy cohort studies: The
Norwegian Mother and Child Cohort Study (MoBa) [20] and the
Avon Longitudinal Study of Parents and Children (ALSPAC) from
the UK [21].
2. Materials and methods
2.1. The Norwegian Mother and Child Cohort Study (MoBa)
Study population and sample acquisition. The Norwegian
Mother and Child Cohort Study (MoBa) is a population-based
pregnancy cohort administered by the Norwegian Institute of
Public Health (NIPH) [20,22,23].
Pregnant women were recruited between 1999 and 2008 from
50 of the 52 hospitals in Norway when attending the routine
ultrasound examination at approximately 18 weeks of gestation
(98% coverage of all pregnant women). The overall participation
rate for MoBa was 41% [20]. Blood samples were drawn from the
mother and blood from the umbilical cord vein was collected with
a syringe. The handling and quality assurance of the biological
material has been thoroughly described previously [24].
The present study is based on data from MoBa version VI
(108,863 children in total) with linkage to the Medical Birth
Registry of Norway (MBR). Participants constituted two subgroups.
The ﬁrst included a sample among those born between July 2002
and December 2003 with completed questionnaires at 18–22
weeks gestation (n = 17,005 eligible children). The second sub-
group included children born between July 2002 and July 2004
with completed questionnaires up to 36 months who were
classiﬁed as having asthma at 36 months. From these two groups,
there were 819 children with maternal 25-hydroxyvitamin D levels
and cord blood DNA methylation proﬁles [25]. The study was
approved by the Norwegian Data Inspectorate and the Regional
Ethics Committee for Medical Research.
25-Hydroxyvitamin D levels. Maternal plasma levels of 25-
hydroxyvitamin D3 and 25-hydroxyvitamin D2 were analyzed at
Bevital laboratories (www.Bevital.no), using a liquid chromatog-
raphy-tandem mass spectrometry method (LC–MS/MS) [25]. The
within day coefﬁcient of variance for 25-hydroxyvitamin D2 was
4.3–4.5%, while the between day coefﬁcient of variance was 4.6–
7.7%. The within day coefﬁcient of variance for 25-hydroxyvitamin
D3was 4.4–5.3%, while the between day coefﬁcient of variance was
7.3–8.2%. The contribution of 25-hydroxyvitamin D2 in the study
sample was negligible, and the sum of 25-hydroxyvitamin D3 and
-D2, termed 25(OH)D, was used in the analysis.
DNA methylation proﬁle generation. Cord blood DNA
methylation was assayed using the Illumina Inﬁnium Human-
Methylation450 BeadChip (www.illumina.com), which was
designed to conduct epigenome-wide association studies (EWAS)
Fig. 1. Association statistics consistent with null distributions. Volcano- and qq-plots for regression models having offspring methylation betas as the response variable and
maternal vitamin D levels as the explanatory variable for both MoBa (left) and ALSPAC (rights) cohorts.
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nucleotide resolution. This chip covers 99% of RefSeq genes, with
an average of 17CpG sites per gene region across the promoter,
50UTR, ﬁrst exon, gene body, and 30UTR. In addition, the chip covers
96% of CpG islands, with additional coverage of island shores. DNA
methylation levels of CpG sites is detected using bisulﬁte-
converted genomic DNA (gDNA), where unmethylated (Un)
cytosine bases are converted to uracil, while methylated (Me)
cytosine remains unchanged. Bisulﬁte conversion was performed
using the EZ-96 DNA Methylation kit (Zymo Research Corporation,
Irvine, CA) according to manufacturer instructions. Illumina
reports an average Beta value for the methylation level of the
interrogated sites based on the following formula: bij = Max(Meij,
0)/(Max (Meij, 0) + Max (Unij, 0) + 100), for each person j and each ofthe 485,512 CpG sites i. Batch effects in these analyses were
avoided as all samples were analyzed on the same day, by the same
individual, using the same instrument. As previously described,
chip, chip set and plate were not appreciable sources of variability
[26,27], so they were not included as covariates in regression
models. BMIQ was performed on the methylation data to
assimilate type I and II probes [28,29]. More information regarding
quality control of the MoBa cohort dataset can be found elsewhere
[26,27].
Statistical analyses. MM type robust linear regression [30] was
carried out with CpG values (0  b  1) as outcome and plasma 25
(OH)D as the explanatory variable. MM type regression is very
robust to outliers (breakdown point when 50% incorrect observa-
tions compared to 1% for ordinary least squares). It is superior to
Fig. 2. Study effect sizes not correlated between MoBa and ALSPAC. Each scatterplot shows the effect sizes of the top 20 meta-analyzed associations. The left plot shows the
effect sizes for the crude model (no covariates), and the right plot shows those for the full model. The dashed lines mark the 95% conﬁdence interval for the regression line.
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coefﬁcient estimates and standard errors rather than just standard
errors. The 25(OH)D explanatory variable was approximately
normally distributed. All p-values and regression estimates
reported are for 25(OH)D in nmol/l as a continuous variable,
categorizing the 25(OH)D variable into quartiles made no
difference. In the primary analysis, the models were adjusted for
maternal pre-pregnancy body mass index (BMI, continuous),
offspring sex, maternal education (4 categories), maternal smoking
(yes/no), maternal folate plasma values (continuous), parity (3
categories), maternal age (continuous), birth season (four catego-
ries) and estimated cell type proportions (continuous matrix
consisting of 6 (default) blood cell-types: CD4+ T cells, CD8+ T cells,
NK-cells, B-cells, monocytes and granulocytes). The cell-type
estimations were calculated with the minﬁ package [31], which is
based on the method described by Houseman et al. [32]. In a
sensitivity analysis, we ran additional models adjusting for various
subsets of the covariates mentioned above:
Model 1. None
Model 2. Maternal Age + Folate + Offspring gender + Houseman
cell counts
Model 3. Model 2 + Season
Model 4. Model 2 + Maternal education + Maternal smoking +
Parity + Maternal BMI
Model 5. Model 4 + Season
We refer to the ﬁrst as the ‘crude’ model and the last as the ‘full’
model.
We used the genomic control (lGC) [33] to assess model quality
and all models tested were found to have lGC close to one. A lGC
close to one suggests that the assumption of independent and
identically distributed tests is fulﬁlled indicating that the less
conservative FDR-based q-values [34] can be used to assess
signiﬁcance in the genome-wide models. Since none of the models
produced any associations with FDR < 0.05 and concordant effect
sizes, only the results from the crude analysis including no
covariates are presented. The meta-analysis was performed using
the Fisher method [35] on all the (2) 473,731 p-values from bothMoBa and ALSPAC crude models and FDR adjusted for multiple
testing.
2.2. The Avon Longitudinal Study of Parents and Children study
(ALSPAC)
Study population and sample acquisition. This study used
DNA methylation data generated under the auspices of the Avon
Longitudinal Study of Parents and Children (ALSPAC) [21,36,37].
DNA extracted from cord blood and peripheral blood samples
along with a wide range of exposure and phenotypic data were
used.
25-Hydroxyvitamin D levels. Approximately a quarter of the 25
(OH)D samples were collected in each of the ﬁrst two trimesters
and half in the third trimester of pregnancy. Because 25(OH)D
levels are known to ﬂuctuate during the year (season) and perhaps
by gestational week, 25(OH)D were pre-adjusted for season and
gestational age at blood sample collection as previously described
[38].
DNA methylation proﬁle generation. Cord blood DNA
methylation was assayed using the Illumina HumanMethyla-
tion450 platform and data pre-processed using procedures
identical to those used for the MoBa dataset. Bisulﬁte conversion
was performed using the EZ DNA Methylation kit (Zymo Research
Corporation, Irvine, CA) according to manufacturer instructions.
All steps were performed at the University of Bristol as part of the
Accessible Resource for Integrated Epigenomic Studies (ARIES)
project (http://www.ariesepigenomics.org.uk). During the data
generation process a wide range of batch variables were recorded
in a purpose-built laboratory information management system
(LIMS). The LIMS also reported QC metrics from the standard
control probes on the 450 K BeadChip. Samples failing quality
(samples with >20% probes with p-value > = 0.01) were repeated.
Samples from all three time points in ARIES were randomized
across arrays to minimize the potential for batch effects. As an
additional QC step, genotype probes on the 450 K BeadChip were
compared between samples from the same individual and against
Fig. 3. MoBa regression coefﬁcient estimate conﬁdence intervals typically contain zero. Estimated slope between DNA methylation levels of offspring CpG sites and maternal
vitamin D levels from the crude model for 4 candidate genes in the MoBa study. The horizontal axis represents the genomic positions of the CpGs, while the vertical axes
represent slope estimates. The vertical lines represent 1.96  estimated standard error for the regression coefﬁcient.
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ALSPAC samples were not analyzed in a single day as were the
MoBa samples. Consequently, the dataset was normalized using an
alternative approach optimized to minimize the effects of resulting
technical artefacts. Speciﬁcally, data normalization included
background correction and subset quantile normalization using
the pipeline described by Touleimat and Tost [39] and imple-
mented in the watermelon R package [29].
2.3. Statistical analyses
Associations between DNA methylation and 25(OH)D were
tested using procedures and covariate subsets identical to thoseused for the MoBa study. The only exception was that maternal
plasma folate was omitted as it has not been measured in ALSPAC.
Due to potentially lingering batch effects present following
normalization, additional analyses were performed that included
covariates generated using independent surrogate variable analy-
sis (ISVA) [40]. Two versions were considered called ‘isva0’ and
‘isva1’. In ‘isva0’, ISVA was applied to the 25(OH)D levels and DNA
methylation data. In ‘isva1’, ISVA was applied as in ‘isva0’ but
additionally all covariates, a batch variable (sample plate), and all
‘isva0’ surrogate variables were included as input for generating
surrogate variables. The results ‘isva0’/’isva1’ were meta-analyzed
with results from the crude/full MoBa models.
Fig. 4. ALSPAC regression coefﬁcient estimate conﬁdence intervals typically contain zero. Estimated slope between methylation levels of offspring CpG sites and maternal
vitamin D levels from the crude model for 4 candidate genes in the ALSPAC study. The horizontal axis represents the genomic positions of the CpGs, while the vertical axes
represent slope estimates. The vertical lines represent 1.96  estimated standard error for the regression coefﬁcient.
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There was no association between mid-pregnancy 25(OH)D and
cord blood DNA methylation at any single site on the Illumina
HumanMethylation450 BeadChip among the 819 mother and
child-pairs in MoBa and the 597 mother and child-pairs in ALSPAC
(at FDR < 0.05; 473,731 tests). Adjustment for potential confound-
ing variables (See Table 1, as well as the Materials and Methods
section) and cell-type estimations as well as a meta-analysis, based
on Fisher's method, comprising results from both MoBa and
ALSPAC cohorts did not result in any association between maternal
25(OH)D levels and DNA methylation in offspring (at FDR < 0.05;
473,731 tests). The 1000 strongest associations are provided in
Supplementary Information ﬁle 1. Regression estimates tended tobe very small, and all p-values were greater than 0.05 after
correction for multiple tests (FDR > 0.2, Bonferroni adjusted p > 0.2,
473731 tests). Fig. 1 shows QQ- and volcano plots for both MoBa
and ALSPAC cohorts based on coefﬁcient estimates and p-values for
473731CpG probes. Fig. 2 shows the lack of agreement in effect
sizes in MoBa and ALSPAC for the top 20 meta-analyzed
associations. Information regarding maternal circulating 25(OH)
D levels and other covariates used throughout the study can be
found in Table 1.
Furthermore, detailed analysis of CpG’s linked to the four a
priori deﬁned candidate genes (CYP24A1, CYP27B1, CYP27A1 and
CYP2R1) yielded weak associations with very small regression
coefﬁcient estimates (Fig. 3; FDR > 0.6 for 56 tests; see Supple-
mentary information File 2). Repeating the analysis within the
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between maternal 25(OH)D and cord blood DNA methylation
among 597 mother and child pairs both at the genome wide and at
the four candidate loci (Fig. 4).
4. Discussion
We explored the potential inﬂuence of maternal mid-pregnan-
cy 25(OH)D on fetal DNA methylation using the Illumina 450 K
BeadChip. Despite the existing hypothesis that maternal vitamin D
status may inﬂuence offspring health [41], we found no evidence
for any DNA methylation based effect in cord blood, either
genome-wide or in four candidate genes.
The strength of our study is the large sample size from two well-
characterized cohorts with 25(OH)D status and genome-wide
Illumina HumanMethylation450k data available for a total of 1416
mother and child-pairs. Despite the fact that the Illumina
HumanMethylation450 BeadChip only covers 485512CpG sites
out of a possible 28 million, most of the targeted sites are found in
the promoter region [42] which is the predominant region
reported to inﬂuence gene expression with regards to circulating
25(OH)D levels [19,43,44]. Epigenetic effects of maternal vitamin D
levels on offspring methylomes can nevertheless not be excluded;
the CpG’s in the neighborhood of the candidate genes, as mapped
by the Illumina HumanMethylation450 BeadChip, may not be the
same as the ones reported from other studies. Although the sample
size is relatively large compared to previous DNA methylation
studies, it may possibly be too small to detect weak epigenetic
effects.
Our analysis in both cohorts was limited to cord blood DNA
methylation. It is possible that DNA methylation levels are strongly
affected by maternal 25(OH)D levels in some other tissue. Analysis
was complicated by the fact that cord blood is composed of several
different ﬂuctuating cell types, each with their own distinct DNA
methylation proﬁles. We attempted to control for this by including
estimates of cell type proportions in regression models [32].
Although this approach is not ideal, it is currently the only feasible
solution [45]. We did not observe strong associations with 25(OH)
D using regression models that included nor excluded cell count
estimates.
We are not aware of any previously published studies of
maternal 25(OH)D and cord blood DNA methylation. However, a
few other studies have explored relationships between vitamin D
supplementation or circulating 25(OH)D and methylation at a few
CpG sites in two to four candidate genes in adults [18,46], and one
genome-wide DNA methylation study explored association with
vitamin D deﬁciency in African children [17].
Given that vitamin D status ﬂuctuates throughout pregnancy, it
is possible that the fetus is more sensitive to vitamin D levels at
certain gestational periods [6]. In the MoBa study, measurements
were taken around 18 weeks gestation, and in the ALSPAC study
they were measured throughout pregnancy but normalized to 28
weeks gestation. It is therefore possible that measurements at
other time points might have provided stronger associations with
cord blood DNA methylation. Hopefully future studies will be
designed to systematically investigate timing.
5. Conclusions
We found no strong associations between DNA methylation in
neonatal genomes and maternal plasma 25(OH)D concentration.
Further scrutiny of a set of speciﬁc candidate genes did not indicate
any association. Our results suggest that similarly powered studies
of maternal 25(OH)D in relation to cord blood DNA methylation
with the Illumina HumanMethylation450 BeadChip will beunlikely to identify true associations, if they exist. Any future
study should utilize DNA methylation proﬁles of alternative cell
types, expanded genomic coverage, larger sample sizes, or
measurements of 25(OH)D at different gestational time points.
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